Collegium Pharmaceutical, Inc. (COLL)Officer sold ~$146K

~$146K

Approx. value · 3,559 sh @ $40.99

72K

Holds after · shares reported

Traded

Mar 3, 2026

Filed

Mar 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Feb 26, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
2. Mar 3, 2026 · this disclosureInsiderOfficer sold ~$146K of COLL shares in the open market

What came next

1. Mar 3, 2026InsiderOfficer sold ~$1.87M of COLL shares in the open market
2. Mar 9, 2026InsiderOfficer sold ~$228K of COLL shares in the open market
3. Mar 18, 2026InsiderOfficer sold ~$488K of COLL shares in the open market
4. Mar 19, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
5. Apr 2, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 6, 2026, the board of directors (“Board”) of Collegium Pharmaceutical, Inc. (the “Company”) approved the nomination of Michael Donovan to stand for election at the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”).”
6. May 7, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
7. May 11, 2026InsiderDirector sold ~$323K of COLL shares in the open market
8. May 12, 2026Company filing · Form 8-K · Acquisition or sale, Executive changeCompleted buying or selling a business or assets, and changed a top executive or board member (and 1 more item)“On May 11, 2026, the Company’s board of directors adopted the Company’s 2026 Inducement Plan (the “ Inducement Plan ”), pursuant to which the Company may grant non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, and dividend equivalent rights with respect to an aggregate of 325,000 shares of the Company’s common stock, par value $0.001…”
9. May 13, 2026InsiderDirector sold ~$162K of COLL shares in the open market
10. May 15, 2026InsiderDirector sold ~$143K of COLL shares in the open market
11. May 18, 2026InsiderDirector sold ~$681 of COLL shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Collegium Pharmaceutical, Inc.

For Collegium Pharmaceutical, Inc., OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its COLL page.

Other recent filings by Scott Dreyer, EVP & Chief Commercial Officer

• SEC Form 4 at Collegium Pharmaceutical, Inc. (COLL)Mar 5, 2026
• SEC Form 4 at Collegium Pharmaceutical, Inc. (COLL)Dec 10, 2025
• SEC Form 4 at Collegium Pharmaceutical, Inc. (COLL)Dec 10, 2025
• SEC Form 4 at Collegium Pharmaceutical, Inc. (COLL)Aug 20, 2025
• SEC Form 4 at Collegium Pharmaceutical, Inc. (COLL)Aug 15, 2025

The full history of Scott Dreyer, EVP & Chief Commercial Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Collegium Pharmaceutical, Inc.

• SEC Form 13F-HRAug 14, 2026
• SEC Form 4May 20, 2026
• SEC Form 4May 18, 2026
• SEC Form 4May 15, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRMay 15, 2026

Everything OQRO holds on this company is on its COLL page.